Effect of Progressive Addition Lenses on Myopia Progression in Japanese Children: A Prospective, Randomized, Double-Masked, Crossover Trial

2008 ◽  
Vol 49 (7) ◽  
pp. 2781 ◽  
Author(s):  
Satoshi Hasebe ◽  
Hiroshi Ohtsuki ◽  
Takafumi Nonaka ◽  
Chiaki Nakatsuka ◽  
Manabu Miyata ◽  
...  
Keyword(s):  
Crossover Trial ◽  
Japanese Children ◽  
Myopia Progression ◽  
Progressive Addition Lenses

Seasonal variation in myopia progression and axial elongation: an evaluation of Japanese children participating in a myopia control trial

2012 ◽  
Vol 56 (4) ◽  
pp. 401-406 ◽  
Author(s):  
Miyuki Fujiwara ◽  
Satoshi Hasebe ◽  
Risa Nakanishi ◽  
Kohhei Tanigawa ◽  
Hiroshi Ohtsuki
Keyword(s):  
Seasonal Variation ◽  
Japanese Children ◽  
Myopia Progression ◽  
Axial Elongation ◽  
Myopia Control

The Effect of Antiplatelet Drugs on Plasma Betathromboglobulin in Coronary Artery Disease

1979 ◽  
Author(s):  
P Han ◽  
A Turpie ◽  
E Genton ◽  
M Gent
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Crossover Trial ◽  
Specific Protein ◽  
Antiplatelet Drugs ◽  
Significant Difference ◽  
Pre Treatment ◽  
Artery Disease ◽  
Therapeutic Doses ◽  
Granule Release

Platelets play a role in the development and complications of coronary artery disease (CAD) and a number of abnormalities of platelet function which can be corrected by antiplatelet drugs have been described. Betathromboglobulin (BTG), a platelet-specific protein which is released from α-granules during platelet activation is significantly elevated in patients with angiographically demonstrated CAD (51.0 ± 31.0 ng/ml., n = 50) compared to normal (28.0 ± 8.0 ng/ml., n = 70) p < 0.001. The effect of sulphinpyrazone (800 mg.) or aspirin (1200 mg.)/dipyridamole (200 mg.) on plasma BTG in CAD was studied in a blind prospective crossover trial in 25 patients. Mean BTG concentration pre-treatment was 52.3 ng/ml. and after 1 month’s treatment with placebo, sulphinpyrazone or aspirin/dipyridamole mean plasma BTG concentrations were 53.5, 49.6 and 56.7 ng/ml. respectively. Analysis of variance showed no significant difference between the means (p > 0.1) . This study confirms increased plasma BTG concentrations in patients with CAD and indicates that therapeutic doses of these antiplatelet drugs do not significantly effect the BTG level and thus appear not to prevent α-granule release in CAD.

Sign in / Sign up

Export Citation Format

Share Document